Occult Hepatitis B (OBH) in Clinical Settings titis B surface antigen mutants. AIDS. 2004;18(3):569-71. 30. Liu CJ, Chen PJ, Chen DS. Dual chronic hepatitis B virus and hepa- titis C virus infection. Hepatol Int. 2009. 31. Sagnelli E, Imparato M, Coppola N, Pisapia R, Sagnelli C, Messina V, et al. Diagnosis and clinical impact of occult hepatitis B infec- tion in patients with biopsy proven chronic hepatitis C: a multi- center study. J Med Virol. 2008;80(9):1547-53. 32. Giannini E, Ceppa P, Botta F, Fasoli A, Romagnoli P, Ansaldi F, et al. Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prev- alence and pathogenicity in hepatitis C virus-positive patients. Liver Int. 2003;23(1):12-8. 33. Brechot C, Jaffredo F, Lagorce D, Gerken G, Meyer zum Buschen- felde K, Papakonstontinou A, et al. Impact of HBV, HCV and GBV- C/HGV on hepatocellular carcinomas in Europe: results of a Euro- pean concerted action. J Hepatol. 1998;29(2):173-83. 34. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341(1):22-6. 35. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2(8):479-86. 36. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004;126(1):102-10. 37. Minuk GY, Sun DF, Uhanova J, Zhang M, Caouette S, Nicolle LE, et al. Occult hepatitis B virus infection in a North American com- munity-based population. J Hepatol. 2005;42(4):480-5. 38. Raimondo G. Occult hepatitis B virus infection and liver disease: fact or fiction? J Hepatol. 2001;34(3):471-3. 39. Cooper C, Kilby D. Clinical significance of hepatitis B core anti- body positivity in HCV-infected and HCV/HIV coinfected individ- uals. Clin Infect Dis. 2004;38(9):1335-7. 40. Selim HS, Abou-Donia HA, Taha HA, El Azab GI, Bakry AF. Role of occult hepatitis B virus in chronic hepatitis C patients with flare of liver enzymes. Eur J Intern Med. 2011;22(2):187-90. 41. Toyoda H, Kumada T, Kaneoka Y, Murakami Y. Impact of hepatitis B virus (HBV) X gene integration in liver tissue on hepatocellular carcinoma development in serologically HBV-negative chronic hepatitis C patients. J Hepatol. 2008;48(1):43-50. 42. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, Piccinino F. HCV genotype and “silent” HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol. 2001;64(3):350-5. 43. Fukuda R, Ishimura N, Hamamoto S, Moritani M, Uchida Y, Ishi- hara S, et al. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon re- ceptor gene expression in the liver. J Med Virol. 2001;63(3):220-7. 44. Mrani S, Chemin I, Menouar K, Guillaud O, Pradat P, Borghi G, et al. Occult HBV infection may represent a major risk factor of non- response to antiviral therapy of chronic hepatitis C. J Med Virol. 2007;79(8):1075-81. 45. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Co- lombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49(4):652-7. 46. Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol. 2006;35(1):14-20. 47. Gupta S, Singh S. Occult hepatitis B virus infection in ART-naive HIV-infected patients seen at a tertiary care centre in north India. BMC Infect Dis. 2010;10:53. 48. Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. Increased detection of HBV DNA in HBsAg-positive and HBsAg- negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J Med Virol. 2009;81(3):406-12. 49. Hofer M, Joller-Jemelka HI, Grob PJ, Luthy R, Opravil M. Frequent chronic hepatitis B virus infection in HIV-infected patients posi- tive for antibody to hepatitis B core antigen only. Swiss HIV Co- hort Study. Eur J Clin Microbiol Infect Dis. 1998;17(1):6-13. 50. Rodriguez-Torres M, Gonzalez-Garcia J, Brau N, Sola R, Moreno S, Rockstroh J, et al. Occult hepatitis B virus infection in the setting Alavian S M et al. of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem? J Med Virol. 2007;79(6):694-700. 51. Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepati- tis B in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;36(3):869-75. 52. Hu KQ. Occult hepatitis B virus infection and its clinical implica- tions. J Viral Hepat. 2002;9(4):243-57. 53. Filippini P, Coppola N, Pisapia R, Scolastico C, Marrocco C, Zac- cariello A, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20(9):1253- 60. 54. Morsica G, Ancarani F, Bagaglio S, Maracci M, Cicconi P, Cozzi Lepri A, et al. Occult hepatitis B virus infection in a Cohort of HIV-positive patients: Correlation with hepatitis C virus coin- fection, virological and immunological features. Infection. 2009;37(5):445-9. 55. Benhamou Y. Antiretroviral therapy and HIV/hepatitis B virus coinfection. Clin Infect Dis. 2004;38 (Suppl 2):S98-103. 56. Lo Re V, 3rd, Frank I, Gross R, Dockter J, Linnen JM, Giachetti C, et al. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr. 2007;44(3):315-20. 57. Lo Re V, 3rd, Wertheimer B, Localio AR, Kostman JR, Dockter J, Linnen JM, et al. Incidence of transaminitis among HIV-infected patients with occult hepatitis B. J Clin Virol. 2008;43(1):32-6. 58. Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, Johnson M, et al. Predictors and kinetics of occult hepatitis B virus infec- tion in HIV-infected persons. J Med Virol. 2007;79(10):1464-71. 59. Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS. 2008;22(12):1399-410. 60. Fang Y, Teng X, Xu WZ, Li D, Zhao HW, Fu LJ, et al. Molecular char- acterization and functional analysis of occult hepatitis B virus infection in Chinese patients infected with genotype C. J Med Vi- rol. 2009;81(5):826-35. 61. Chan HL, Tsang SW, Leung NW, Tse CH, Hui Y, Tam JS, et al. Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. Am J Gastroenterol. 2002;97(5):1211-5. 62. Hou J, Wang Z, Cheng J, Lin Y, Lau GK, Sun J, et al. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepa- tology. 2001;34(5):1027-34. 63. Al-Mahtab M, Rahman S, Khan M. Occult Hepatitis B Virus Related Decompensated Cirrhosis of Liver in Young Males: First Report of Two Cases from Bangladesh. Hepat Mon. 2008;8(2):147-50. 64. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini- Brechot P. Persistent hepatitis B virus infection in subjects with- out hepatitis B surface antigen: clinically significant or purely “occult”? Hepatology. 2001;34(1):194-203. 65. Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann In- tern Med. 2007;146(9):649-56. 66. Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, et al. Occult hepatitis B virus in liver tissue of indi- viduals without hepatic disease. J Hepatol. 2008;48(5):743-6. 67. Shiota G, Oyama K, Udagawa A, Tanaka K, Nomi T, Kitamura A, et al. Occult hepatitis B virus infection in HBs antigen-negative he- patocellular carcinoma in a Japanese population: involvement of HBx and p53. J Med Virol. 2000;62(2):151-8. 68. Chen CH, Changchien CS, Lee CM, Tung WC, Hung CH, Hu TH, et al. A study on sequence variations in pre-S/surface, X and enhanc- er II/core promoter/precore regions of occult hepatitis B virus in non-B, non-C hepatocellular carcinoma patients in Taiwan. Int J Cancer. 2009;125(3):621-9. 69. Paterlini P, Driss F, Nalpas B, Pisi E, Franco D, Berthelot P, et al. Persistence of hepatitis B and hepatitis C viral genomes in pri- mary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology. 1993;17(1):20-9. 70. Michalak TI, Pardoe IU, Coffin CS, Churchill ND, Freake DS, Smith Hepat Mon. 2012;12(8):e6126 Published by Kowsar, © BRCGL 2012 7